In aggressive clear cell renal cell carcinoma, the ECT2 expression correlated with pituitary tumor-transforming 1 (PTTG1) expression and poor clinical outcomes, suggesting a possible downstream molecular mechanism whereby ECT2 promoted cancer malignancy [34]. This evidence concerns the gene ECT2 and cancer.